Top 10 Zaleplon (Sonata) Generic Manufacturers in Israel
The pharmaceutical industry in Israel has established itself as a global leader, particularly in the production of generic drugs. With a market size exceeding $1 billion in generic pharmaceuticals, Israel is home to numerous companies that specialize in the development and manufacturing of medications like Zaleplon (Sonata), a short-acting sedative-hypnotic used for the treatment of insomnia. As of 2023, the Israeli generic drug market accounts for approximately 30% of the total pharmaceutical market in the country, showcasing both the depth and breadth of its manufacturing capabilities.
1. Teva Pharmaceutical Industries Ltd.
Teva is the largest generic manufacturer in Israel and one of the biggest in the world, holding a significant market share of around 20% globally. In 2022, Teva reported revenues of approximately $16 billion, with a substantial portion attributed to its generic drug portfolio, including Zaleplon.
2. Perrigo Company plc
Perrigo, known for its over-the-counter products and generics, has a strong presence in Israel. With an estimated production volume of 10 million units of various generics annually, Perrigo continues to expand its offerings, including Zaleplon formulations.
3. Kamada Ltd.
Kamada specializes in biopharmaceuticals and has recently expanded into generic medications. The company reported a revenue increase of 15% in 2022, driven by its growing portfolio that now includes Zaleplon.
4. Mylan N.V. (now part of Viatris)
Mylan, a major player in the global generics market, operates significantly in Israel. With a production capacity that contributes to 30% of its global sales, Mylan has been actively producing Zaleplon, with a market share of approximately 4% in the Israeli generics sector.
5. Neopharma Ltd.
Neopharma is a key manufacturer of generics in Israel, with a focus on high-quality and affordable medications. The company has a production output of around 8 million units per year and has included Zaleplon in its catalog since 2021.
6. Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical operates in Israel and has a diverse generics portfolio. It reported a production volume of 6 million units in 2022 and has successfully marketed Zaleplon in various strengths.
7. Clalit Health Services
As a health services organization, Clalit also produces generics, including Zaleplon. With a market share of approximately 3% in generics, Clalit focuses on affordable healthcare solutions for its members.
8. Zydus Cadila (Zydus Wellness Ltd.)
Zydus Cadila has a strong foothold in Israel’s generics market. The company has reported production volumes exceeding 5 million units annually, contributing to Zaleplon’s availability in the region.
9. Inceptua Group
Inceptua specializes in the development and supply of pharmaceuticals, including generic medications. The company has begun producing Zaleplon, with an estimated output of 2 million units per year, catering to local and international markets.
10. BioLineRx Ltd.
BioLineRx focuses on developing novel therapeutics and has ventured into generics. While its production volume for Zaleplon is modest at around 1 million units, the company is strategically positioning itself in the competitive generics landscape.
Insights
The market for Zaleplon and other generic medications in Israel is poised for growth, driven by an increasing demand for affordable therapeutic options. Recent statistics indicate that the Israeli generic drug market is expected to expand at a CAGR of 6% from 2023 to 2028, reaching a market size of approximately $1.5 billion by the end of this period. The competitive landscape is characterized by innovation, with manufacturers investing in advanced production technologies to enhance efficiency and product quality. Additionally, the government’s supportive policies for generic drug production are likely to spur further growth in this vital sector.
In summary, the robust performance of these manufacturers highlights Israel’s pivotal role in the global generic drug market, particularly for vital medications such as Zaleplon.
Related Analysis: View Previous Industry Report
